Literature DB >> 10774481

The genetics of the amyloidoses.

J N Buxbaum1, C E Tagoe.   

Abstract

The amyloidoses are diseases in which abnormalities in the secondary structure of precursor proteins result in decreased solubility under physiologic conditions, with subsequent organ compromise. A total of 18 proteins have been definitively identified as amyloid precursors associated with human disease. Mutations in the genes that encode some of these proteins produce autosomal dominant disease in mid to late adult life. Until recently, the late onset has obscured the familial nature of some of the disorders. This is especially true in the apparently sporadic disease-producing deposits found even later in life. In many instances, these deposits are derived from precursors encoded by wild-type genes (perhaps influenced by alleles that are polymorphic in the normal population); in other cases, they represent autosomal dominant disease with age-dependent penetrance. The genetic aspects of amyloid diseases produced by the deposition of four different proteins have been investigated in detail and provide insights into the particular diseases and amyloidogenesis in general.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10774481     DOI: 10.1146/annurev.med.51.1.543

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  26 in total

1.  Formation of Hirano bodies induced by expression of an actin cross-linking protein with a gain-of-function mutation.

Authors:  Andrew Maselli; Ruth Furukawa; Susanne A M Thomson; Richard C Davis; Marcus Fechheimer
Journal:  Eukaryot Cell       Date:  2003-08

2.  Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins.

Authors:  Gal Bitan
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

Review 3.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

4.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.

Authors:  X Jiang; J N Buxbaum; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

5.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

6.  Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease.

Authors:  R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Biochemistry       Date:  2005-12-20       Impact factor: 3.162

7.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

8.  Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition.

Authors:  C Poitou; N Viguerie; R Cancello; R De Matteis; S Cinti; V Stich; C Coussieu; E Gauthier; M Courtine; J D Zucker; G S Barsh; W Saris; P Bruneval; A Basdevant; D Langin; K Clément
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

9.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

10.  Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.

Authors:  Satheesh K Palaninathan; Nilofar N Mohamedmohaideen; Elisabetta Orlandini; Gabriella Ortore; Susanna Nencetti; Annalina Lapucci; Armando Rossello; Joel S Freundlich; James C Sacchettini
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.